Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
7,096,625
-
Total 13F shares
-
6,034,640
-
Share change
-
+793,741
-
Total reported value
-
$365,700,278
-
Price per share
-
$60.66
-
Number of holders
-
62
-
Value change
-
+$48,630,884
-
Number of buys
-
37
-
Number of sells
-
14
Institutional Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) as of Q3 2025
As of 30 Sep 2025,
BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,034,640 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, Cormorant Asset Management, LP, Vivo Capital, LLC, Commodore Capital LP, PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BRAIDWELL LP, BlackRock, Inc., MORGAN STANLEY, and Sio Capital Management, LLC.
This page lists
62
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.